Pharmacokinetics Evaluation of Vitamin D Formulations

Pharmacokinetics Evaluation of Different Vitamin D3 Formulations

The primary objective of this study is to evaluate plasma concentrations of Vitamin D (25-hydroxyvitamin D; 1,25-dihydroxyvitamin D) of different Vitamin D formulations in healthy volunteers at two concentrations. Pharmacokinetic parameters (Serum 25(OH)D and 1,25(OH)2D ng/ml) are compared with those of a regular Vitamin D formulation and a new (microencapsulated) LipoMicel Vitamin D formulation.

The secondary objective of this study is to evaluate safety blood parameters- The following blood parameters (serum levels) are checked: Alkaline Phosphatase, ALT, AST, Bilirubin, CRP, Creatinine, GGT. In addition, mineral levels-such as calcium, magnesium and phosphorus, potassium and sodium-are measured before and at the end of the study.

Study Overview

• Status: Completed
• Conditions: Vitamin D
• Intervention / Treatment: Dietary supplement: Vitamin D3

Detailed Description

Study Design:

At least 40 healthy volunteers of both sexes in the age range 21-65 participate in a parallel, randomized blinded study conducted with different vitamin D3 products.

Each treatment is administered orally per day at a total dose of 1000 UI and 2500 IU vitamin d3 (cholecalciferol), together with breakfast, over a period of 30 days.

Participants are randomly divided into 4 groups (at least 10 per group):

The first group receives regular Vitamin D (1000IU), the second receives microencapsulated D3 (1000IU), the third group receives regular Vitamin D (2500IU), the fourth receives microencapsulated D3 (2500 IU).

Plasma concentrations (serum levels) of Vitamin D (25(OH)D and 1,25(OH)2D ng/ml are measured at baseline-before treatment start (day 0), during treatment (day 5, 10 and 15; one blood collection per day) and at end of treatment (day 30).

After the end of supplementation, blood vitamin D concentrations are checked again at day 45 and day 60.

The entire study session will span the course of 60 days. Participants are asked to attend 7 visits at LifeLabs to collect venous blood samples.

Each Vitamin D treatment is consumed with a glass of water along with breakfast for a period of 30 days.

Safety blood work is performed upon study enrolment, at the end of the Vitamin supplementation (day 30)- and at the end of the study (day 60) at Life Labs.

The following blood parameters are checked and must be within normal ranges to participate the study: Alkaline Phosphatase, ALT, AST, Bilirubin, CRP, Creatinine, GGT.

Mineral levels-such as calcium, magnesium and phosphorus-are measured before and at the end of the study (day 30).

All participants must understand written and spoken English and give written informed consent before any study specific procedure will be carried out.

All tested products are formulation manufactured by Factors Group.

• Study Type: Interventional
• Enrollment (Actual): 37
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Julia Solnier, Dr.; Phone Number: +1 604-415-4185; Email: jsolnier@factorsgroup.com

Study Locations

• Canada
  • British Columbia
    • Coquitlam, British Columbia, Canada, V3K 6Y2
      • Natural Factors

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• age between 21 and 65 years; avoid consumption of any additional food supplements containing vitamin D; avoid use of tanning beds or other artificial UVB sources.

Participants must complete an online questionnaire on their medical history, weight, height, lifestyle (smoking, exercising etc.) and dietary habits relating to food rich in vitamin D, including other dietary supplementations.

Exclusion Criteria:

• use of vitamin D, calcium, magnesium, fish oil, or omega 3 fatty acids supplements; history of acute or chronic illness (such as gastrointestinal, liver and kidney disorders, osteoporosis …); pregnancy or lactation.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Regular Vitamin D3 1000IU; The first group receives regular Vitamin D3 1000IU	Dietary supplement: Vitamin D3; Participants are randomly divided into 4 groups. The first group receives regular Vitamin D3 (1000IU), the second receives microencapsulated D3 (1000IU), the third group receives regular Vitamin D3 (2500IU), the fourth receives microencapsulated D3 (2500 IU). Plasma concentrations of Vitamin D (D3, 25(OH)D3 and D2) are measured at baseline-before treatment start (day 0), during treatment (day 14) and at end of treatment (day 30). After the end of supplementation, blood vitamin D concentrations are checked again at day 45 and day 60.
Active Comparator: Microencapsulated Vitamin D3 1000IU; The second group receives microencapsulated Vitamin D3 1000IU	Dietary supplement: Vitamin D3; Participants are randomly divided into 4 groups. The first group receives regular Vitamin D3 (1000IU), the second receives microencapsulated D3 (1000IU), the third group receives regular Vitamin D3 (2500IU), the fourth receives microencapsulated D3 (2500 IU). Plasma concentrations of Vitamin D (D3, 25(OH)D3 and D2) are measured at baseline-before treatment start (day 0), during treatment (day 14) and at end of treatment (day 30). After the end of supplementation, blood vitamin D concentrations are checked again at day 45 and day 60.
Active Comparator: Regular Vitamin D3 2500IU; The third group receives regular Vitamin D3 2500IU	Dietary supplement: Vitamin D3; Participants are randomly divided into 4 groups. The first group receives regular Vitamin D3 (1000IU), the second receives microencapsulated D3 (1000IU), the third group receives regular Vitamin D3 (2500IU), the fourth receives microencapsulated D3 (2500 IU). Plasma concentrations of Vitamin D (D3, 25(OH)D3 and D2) are measured at baseline-before treatment start (day 0), during treatment (day 14) and at end of treatment (day 30). After the end of supplementation, blood vitamin D concentrations are checked again at day 45 and day 60.
Active Comparator: Microencapsulated Vitamin D3 2500IU; The fourth group receives microencapsulated Vitamin D3 2500IU	Dietary supplement: Vitamin D3; Participants are randomly divided into 4 groups. The first group receives regular Vitamin D3 (1000IU), the second receives microencapsulated D3 (1000IU), the third group receives regular Vitamin D3 (2500IU), the fourth receives microencapsulated D3 (2500 IU). Plasma concentrations of Vitamin D (D3, 25(OH)D3 and D2) are measured at baseline-before treatment start (day 0), during treatment (day 14) and at end of treatment (day 30). After the end of supplementation, blood vitamin D concentrations are checked again at day 45 and day 60.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of Vitamin D serum level: change of 1,25-Dihydroxyvitamin D	Venous blood samples are collected to measure concentrations of 1,25-Dihydroxyvitamin D	at day 0 (before treatment), at day 5, 10, 15 (during treatment), at day 30 (end of treatment), at day 45 and 60 (after treatment).
Evaluation of Vitamin D serum level: change of 25-Hydroxyvitamin D	Venous blood samples are collected to measure concentrations of 25-Hydroxyvitamin D	at day 0 (before treatment), at day 5, 10, 15 (during treatment), at day 30 (end of treatment), at day 45 and 60 (after treatment).

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety blood work evaluation - change of aspartate aminotransferase (AST)	Venous blood samples are collected to measure concentrations of AST	at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment).
Safety blood work evaluation - change of alanine aminotransferase (ALT)	Venous blood samples are collected to measure concentrations of ALT	at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment).
Safety blood work evaluation - change of alkaline phosphatase	Venous blood samples are collected to measure concentrations of alkaline phosphatase	at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment).
Safety blood work evaluation - change of bilirubin	Venous blood samples are collected to measure concentrations of total bilirubin	at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment).
Safety blood work evaluation - change of gamma-glutamyl transferase (GGT)	Venous blood samples are collected to measure concentrations of GGT	at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment).
Safety blood work evaluation - change of creatinine	Venous blood samples are collected to measure concentrations of creatinine	at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment).
Safety blood work evaluation - change of C Reactive Protein (CRP)	Venous blood samples are collected to measure concentrations of CRP	at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment).
Safety blood work evaluation - change of mineral levels such as calcium	Venous blood samples are collected to measure concentrations of calcium	at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment).
Safety blood work evaluation - change of mineral levels such as magnesium	Venous blood samples are collected to measure concentrations of magnesium	at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment).
Safety blood work evaluation - change of mineral levels such as phosphate	Venous blood samples are collected to measure concentrations of phosphate	at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment).
Safety blood work evaluation - change of mineral levels such as sodium	Venous blood samples are collected to measure concentrations of sodium	at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment).

Collaborators and Investigators

• Sponsor: Factors Group of Nutritional Companies Inc.

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2022
• Primary Completion (Actual): April 30, 2023
• Study Completion (Actual): April 30, 2023

Study Registration Dates

• First Submitted: December 20, 2021
• First Submitted That Met QC Criteria: January 21, 2022
• First Posted (Actual): January 26, 2022

Study Record Updates

• Last Update Posted (Actual): September 13, 2023
• Last Update Submitted That Met QC Criteria: September 11, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Micronutrients; Vitamins; Bone Density Conservation Agents; Calcium-Regulating Hormones and Agents; Vitamin D; Cholecalciferol
• Other Study ID Numbers: 2021-11-001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No